PL2477699T3 - Zastosowanie medyczne liposomów ulegających hydrolizie pod wpływem sPLA2 - Google Patents

Zastosowanie medyczne liposomów ulegających hydrolizie pod wpływem sPLA2

Info

Publication number
PL2477699T3
PL2477699T3 PL10757705T PL10757705T PL2477699T3 PL 2477699 T3 PL2477699 T3 PL 2477699T3 PL 10757705 T PL10757705 T PL 10757705T PL 10757705 T PL10757705 T PL 10757705T PL 2477699 T3 PL2477699 T3 PL 2477699T3
Authority
PL
Poland
Prior art keywords
spla2
liposomes
influence
medical use
hydrolysable under
Prior art date
Application number
PL10757705T
Other languages
English (en)
Inventor
Morten Just Petersen
Fredrik Melander
Anders Falk Vikbjerg
Sune Allan Petersen
Mogens Winkel Madsen
Original Assignee
Bio-Bedst Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio-Bedst Aps filed Critical Bio-Bedst Aps
Publication of PL2477699T3 publication Critical patent/PL2477699T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL10757705T 2009-09-17 2010-09-16 Zastosowanie medyczne liposomów ulegających hydrolizie pod wpływem sPLA2 PL2477699T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200901037A DK177532B1 (en) 2009-09-17 2009-09-17 Medical use of sPLA2 hydrolysable liposomes
PCT/DK2010/050237 WO2011032563A1 (en) 2009-09-17 2010-09-16 Medical use of spla2 hydrolysable liposomes
EP10757705.8A EP2477699B1 (en) 2009-09-17 2010-09-16 Medical use of spla2 hydrolysable liposomes

Publications (1)

Publication Number Publication Date
PL2477699T3 true PL2477699T3 (pl) 2018-05-30

Family

ID=43066925

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10757705T PL2477699T3 (pl) 2009-09-17 2010-09-16 Zastosowanie medyczne liposomów ulegających hydrolizie pod wpływem sPLA2

Country Status (18)

Country Link
US (2) US20120177726A1 (pl)
EP (1) EP2477699B1 (pl)
JP (3) JP2013505204A (pl)
CN (1) CN102630175B (pl)
AU (1) AU2010294971B2 (pl)
CA (1) CA2772965C (pl)
CY (1) CY1119982T1 (pl)
DK (2) DK177532B1 (pl)
ES (1) ES2658971T3 (pl)
HR (1) HRP20180225T1 (pl)
HU (1) HUE038017T2 (pl)
LT (1) LT2477699T (pl)
NO (1) NO2477699T3 (pl)
PL (1) PL2477699T3 (pl)
PT (1) PT2477699T (pl)
SI (1) SI2477699T1 (pl)
SM (1) SMT201800104T1 (pl)
WO (1) WO2011032563A1 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2123258A1 (en) 2008-05-23 2009-11-25 Liplasome Pharma A/S Liposomes for drug delivery
DK177532B1 (en) 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
US10570457B2 (en) 2014-09-26 2020-02-25 Medical Prognosis Institute A/S Methods for predicting drug responsiveness
US9725769B1 (en) 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
AU2017258901A1 (en) 2016-12-30 2018-07-19 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients
US10925831B2 (en) * 2017-08-28 2021-02-23 Wake Forest University Liposomal formulations of platinum-acridine anticancer agents and methods thereof
AU2019200325A1 (en) * 2018-01-31 2019-08-15 Liplasome Pharma Aps Methods for treating cancer and predicting drug responsiveness in cancer patients
US12194014B2 (en) 2018-06-21 2025-01-14 NanoMed Holdings Pty Ltd Platinum-based amphiphile prodrugs
CN111504995B (zh) * 2020-05-13 2021-10-12 暨南大学 一种基于比色原理检测磷脂酶a2的方法及其应用
CN114276404B (zh) * 2021-12-24 2023-07-25 五邑大学 甘草次酸类甘油磷脂化合物、其分泌型磷脂酶a2敏感性脂质体及其应用
WO2024231432A1 (en) * 2023-05-08 2024-11-14 Chosa Oncology Ab Liposome compositions and medical uses thereof

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880635B1 (en) 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
ES2039203T3 (es) * 1985-11-22 1993-09-16 Takeda Chemical Industries, Ltd. Composicion de liposomas.
US4963362A (en) * 1987-08-07 1990-10-16 Regents Of The University Of Minnesota Freeze-dried liposome mixture containing cyclosporin
US7625697B2 (en) 1994-06-17 2009-12-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for constructing subarrays and subarrays made thereby
WO1996010585A1 (en) * 1994-09-30 1996-04-11 Inex Pharmaceuticals Corp. Glycosylated protein-liposome conjugates and methods for their preparation
US5773027A (en) * 1994-10-03 1998-06-30 Michael G. Bergeron Liposomes encapsulating antiviral drugs
US5858397A (en) * 1995-10-11 1999-01-12 University Of British Columbia Liposomal formulations of mitoxantrone
NZ332578A (en) * 1996-05-09 2000-06-23 Infectio Recherche Inc Gel formulation containing poloxamer compound for use in the prevention of pathogen induced diseases including HIV and HSV
US20040072722A1 (en) 2002-10-10 2004-04-15 Kornblith Paul L. Methods for assessing efficacy of chemotherapeutic agents
AU1656799A (en) 1997-12-12 1999-07-05 Inex Pharmaceuticals Corp. Cationic drugs encapsulated in anionic liposomes
AU3105700A (en) 1998-12-08 2000-06-26 Board Of Regents, The University Of Texas System Methods for detection of antiestrogen-resistant breast cancer
WO2000035473A2 (en) 1998-12-18 2000-06-22 Scios Inc. Methods for detection and use of differentially expressed genes in disease states
US7324926B2 (en) 1999-04-09 2008-01-29 Whitehead Institute For Biomedical Research Methods for predicting chemosensitivity or chemoresistance
US6647341B1 (en) 1999-04-09 2003-11-11 Whitehead Institute For Biomedical Research Methods for classifying samples and ascertaining previously unknown classes
US6911306B1 (en) 1999-10-18 2005-06-28 Emory University TMS1 compositions and methods of use
ES2230268T3 (es) 2000-02-10 2005-05-01 Liplasome Pharma A/S Sistema de liberacion de farmacos basados en lipidos.
ES2295149T3 (es) 2000-04-12 2008-04-16 Liplasome Pharma A/S Sistemas de suministro de farmacos contra infecciones parasiticas.
US20030026831A1 (en) * 2001-04-20 2003-02-06 Aparna Lakkaraju Anionic liposomes for delivery of bioactive agents
CA2383259A1 (en) * 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
JP4822666B2 (ja) * 2001-10-03 2011-11-24 セレーター ファーマシューティカルズ インコーポレイテッド 金属イオンをローディングするリポソーム
US20050118250A1 (en) * 2001-11-13 2005-06-02 Paul Tardi Lipid carrier compositions with enhanced blood stability
US20050118249A1 (en) * 2001-11-13 2005-06-02 Murray Webb Lipid carrier compositions and methods for improved drug retention
JP2006506945A (ja) 2002-03-28 2006-03-02 メディカル・カレッジ・オブ・オハイオ 遺伝子発現プロフィールを使用する非小細胞肺癌の診断および処置のための方法および組成物
US7273620B1 (en) 2002-05-20 2007-09-25 University Of British Columbia Triggered release of liposomal drugs following mixing of cationic and anionic liposomes
US20040018525A1 (en) 2002-05-21 2004-01-29 Bayer Aktiengesellschaft Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasma
US20040022842A1 (en) 2002-06-03 2004-02-05 Mebiopharm Co., Ltd. Liposome preparations containing oxaliplatin
DE60335469D1 (de) * 2002-07-02 2011-02-03 Univ Texas Radioaktiv markierte verbindungen und liposome und ihre herstellungs- und anwendungsverfahren
EP1643971A2 (en) 2003-05-22 2006-04-12 Neopharm, Inc. Liposomal formulations comprising a combination of two or more active agents
US7358046B2 (en) 2003-08-08 2008-04-15 Canbas Co., Ltd. Sensitivity test to predict efficacy of anti-cancer therapies
EP1547674A1 (en) * 2003-12-23 2005-06-29 MediGene Oncology GmbH Method for producing colloidal nanoparticles
US20050147978A1 (en) 2003-12-30 2005-07-07 Jose Remacle Method for quantitative determination of multi-drug resistance in tumors
US7700280B2 (en) 2003-12-31 2010-04-20 The Penn State Research Foundation Methods for assessing cisplatin resistance, disease progression, and treatment efficacy in ovarian cancer
CA2554818A1 (en) 2004-02-09 2005-08-25 Thomas Jefferson University Diagnosis and treatment of cancers with microrna located in or near cancer-associated chromosomal features
US20070270488A1 (en) 2004-03-12 2007-11-22 The Queen's University Of Belfast Treatment and Assays
EP1742650A1 (en) 2004-03-30 2007-01-17 Den Kgl.Veterin R-Og Landboh Jskole Improvements in cancer treatment and cancer treatment efficacy prediction by blocking and detecting protease inhibitors
US7871769B2 (en) 2004-04-09 2011-01-18 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
CA2821167C (en) 2004-05-03 2016-06-28 Merrimack Pharmaceuticals, Inc. Drug delivery liposomes containing anionic polyols or anionic sugars
WO2005111211A2 (en) 2004-05-14 2005-11-24 Rosetta Genomics Ltd. Micronas and uses thereof
WO2006025411A1 (ja) * 2004-08-31 2006-03-09 Astellas Pharm. Inc. 細胞内薬物送達改善リポソーム
DE602005012155D1 (de) 2004-11-03 2009-02-12 Liplasome Pharma As Arzneimittelabgabesysteme auf lipidbasis mit unnatürlichen phospholipase-a2-abbaubaren lipid-derivaten und ihre therapeutische verwendung
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
WO2007038792A2 (en) 2005-09-28 2007-04-05 H. Lee Moffitt Cancer Center Individualized cancer treatments
JP5687411B2 (ja) * 2005-10-25 2015-03-18 セレーター ファーマスーティカルズ、インク． 固形腫瘍のための定率配合薬の治療
US8445198B2 (en) 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
EP1960551A2 (en) 2005-12-01 2008-08-27 Medical Prognosis Institute Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
EP2484782B1 (en) 2006-01-05 2015-11-18 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers
WO2008048342A2 (en) 2006-02-08 2008-04-24 Dharmacon, Inc. Microarray for detecting and quantifying microrna
EP2004236A2 (en) * 2006-03-23 2008-12-24 Liplasome Pharma A/S Lipid based drug delivery systems comprising phospholipase a2 degradable lipids that perform an intramolecular cyclization reaction upon hydrolysis
WO2008006517A2 (en) 2006-07-13 2008-01-17 Siemens Healthcare Diagnostics Gmbh Prediction of breast cancer response to taxane-based chemotherapy
US20080085295A1 (en) 2006-07-14 2008-04-10 Fmc Biopolymer As Hydrogels containing low molecular weight alginates and biostructures made therefrom
US20080076134A1 (en) 2006-09-21 2008-03-27 Nuclea Biomarkers, Llc Gene and protein expression profiles associated with the therapeutic efficacy of irinotecan
US20100178651A1 (en) 2006-11-03 2010-07-15 Christos Hatzis Bifunctional Predictors of Cancer Treatment Sensitivity and Resistance
WO2008089449A2 (en) 2007-01-19 2008-07-24 Biodot, Inc. Systems and methods for high speed array printing and hybridization
WO2008112283A2 (en) 2007-03-12 2008-09-18 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Microrna profiling of androgen responsiveness for predicting the appropriate prostate cancer treatment
WO2008138578A2 (en) 2007-05-11 2008-11-20 Medical Prognosis Institute Methods, kits, and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
EP2198050A1 (en) 2007-09-14 2010-06-23 Asuragen, INC. Micrornas differentially expressed in cervical cancer and uses thereof
US20090162425A1 (en) * 2007-09-19 2009-06-25 University Of Tennessee Research Foundation Methods and compositions for inhibiting undesirable cellular proliferation by targeted liposome delivery of active agents
WO2009052512A2 (en) 2007-10-19 2009-04-23 Cedars-Sinai Medical Center Methods of using genetic variants to diagnose and predict inflammatory bowel disease
WO2009080437A1 (en) 2007-12-21 2009-07-02 Exiqon A/S Micro-rna based drug resistance analysis method
EP2123258A1 (en) * 2008-05-23 2009-11-25 Liplasome Pharma A/S Liposomes for drug delivery
CN102002490A (zh) 2009-08-31 2011-04-06 上海市肿瘤研究所 9个用于预测原发性肝癌是否复发的microRNA标志物
DK177532B1 (en) 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
DK177529B1 (en) 2009-10-23 2013-09-08 Bio Bedst Aps Liposomes with improved storage stability
MX337650B (es) 2009-11-23 2016-03-14 Genomic Health Inc Metodos para predecir el desenlace clinico del cancer.
US20120302626A1 (en) 2009-12-04 2012-11-29 Sandeep Dave Microrna and use thereof in identification of b cell malignancies
WO2011097509A2 (en) 2010-02-05 2011-08-11 Myriad Genetics, Inc. Hypoxia-related gene signatures for cancer classification
WO2011098578A2 (en) 2010-02-12 2011-08-18 Bioneer A/S Liposome system for ocular administration
WO2011113030A2 (en) 2010-03-11 2011-09-15 H.Lee Moffitt Cancer Center & Research Institute Human cancer micro-rna expression profiles predictive of chemo-response
WO2011135459A2 (en) 2010-04-29 2011-11-03 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy
WO2012024543A1 (en) 2010-08-18 2012-02-23 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
US20120046186A1 (en) 2010-08-20 2012-02-23 Pelham Robert J Gene Expression Markers for Prediction of Response to Platinum-Based Chemotherapy Drugs
CA2826657A1 (en) 2011-02-04 2012-08-09 Bioarray Therapeutics, Inc. Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment
WO2012109233A2 (en) 2011-02-07 2012-08-16 Board Of Regents, The University Of Texas System Methods for predicting recurrence risk in breast cancer patients
US20140106986A1 (en) 2011-06-01 2014-04-17 Medical Prognosis Institute A/S Methods and devices for prognosis of cancer relapse
WO2013040393A2 (en) 2011-09-14 2013-03-21 Georgetown University Genes contributing to survival of cancer cells
WO2013130465A2 (en) 2012-02-27 2013-09-06 Genomic Health, Inc. Gene expression markers for prediction of efficacy of platinum-based chemotherapy drugs
US9606123B2 (en) 2013-03-29 2017-03-28 University Of Virginia Patent Foundation Compositions and methods for diagnosing and monitoring ovarian cancer progression and treatment
RU2528247C2 (ru) 2013-05-07 2014-09-10 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Способ оценки чувствительности клеток рака легкого к доксорубицину на основании уровней экспрессии маркерных генов и набор для его осуществления
WO2014195032A1 (en) 2013-06-07 2014-12-11 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy of fulvestrant in cancer patients
US10570457B2 (en) 2014-09-26 2020-02-25 Medical Prognosis Institute A/S Methods for predicting drug responsiveness
US20160199399A1 (en) 2015-01-09 2016-07-14 Medical Prognosis Institute A/S Methods for predicting drug responsiveness in cancer patients
US20180087113A1 (en) 2016-09-27 2018-03-29 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
US9725769B1 (en) 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
AU2017258901A1 (en) 2016-12-30 2018-07-19 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients

Also Published As

Publication number Publication date
HUE038017T2 (hu) 2018-09-28
NO2477699T3 (pl) 2018-04-07
PT2477699T (pt) 2018-02-15
CY1119982T1 (el) 2018-12-12
WO2011032563A1 (en) 2011-03-24
AU2010294971A1 (en) 2012-03-22
DK200901037A (en) 2011-03-18
JP2013505204A (ja) 2013-02-14
CA2772965A1 (en) 2011-03-24
SI2477699T1 (en) 2018-03-30
JP2015127349A (ja) 2015-07-09
ES2658971T3 (es) 2018-03-13
CN102630175B (zh) 2015-11-25
CN102630175A (zh) 2012-08-08
DK177532B1 (en) 2013-09-08
DK2477699T3 (en) 2018-02-12
CA2772965C (en) 2017-08-15
SMT201800104T1 (it) 2018-03-08
EP2477699A1 (en) 2012-07-25
LT2477699T (lt) 2018-02-26
AU2010294971B2 (en) 2015-08-20
EP2477699B1 (en) 2017-11-08
JP2017052790A (ja) 2017-03-16
HRP20180225T1 (hr) 2018-03-09
US20190343766A1 (en) 2019-11-14
US11207269B2 (en) 2021-12-28
US20120177726A1 (en) 2012-07-12

Similar Documents

Publication Publication Date Title
SMT201600254B (it) Procedimento per la preparazione di idromagnesite
PL2506850T3 (pl) Sposoby podawania terapii pirfenidonem
EP2393914A4 (en) LUNG TISSUE ENGINEERING
BRPI1009847A2 (pt) conectores médicos e métodos de uso
HUE054432T2 (hu) Képalkotó rendszer optimalizált kiterjesztett fókuszmélységgel
HUE038017T2 (hu) sPLA2 hidrolizálható liposzómák orvosi alkalmazása
HRP20170961T1 (hr) Postupak dobivanja karbamoilpiridonskih derivata i međuprodukata
IL220876A0 (en) Treatment of cardiac conditions
BR112013011632A2 (pt) cateteres de citorredução flexíveis com imagiologia e métodos de uso e fabricação
EP2474262A4 (en) STEREOSCOPIC ENDOSCOPE
EP2442821A4 (en) SAFE ADMINISTRATION OF DESMOPRESSIN
IT1393136B1 (it) Procedimento per la preparazione del bosentan
GB201100259D0 (en) Management of pool member configuration
DE112011103919A5 (de) Endoskop
ZA201303416B (en) Methods for enhancing oxygenation of jeopardized tissue
IT1403282B1 (it) Procedimento per la preparazione di linagliptin
ZA201102173B (en) Treatment of water
EP2556786A4 (en) Endoscope
IT1395596B1 (it) Procedimento per la preparazione di sitagliptin
PL2407155T3 (pl) Formulacje inekalcytolu
TWM385326U (en) Structure of side-view endoscope
FI20095792L (fi) Ihmissolujen käyttö
TWM388919U (en) Structure of endoscope
IT1398273B1 (it) Procedimento per la preparazione di 14-bromo daunomicina
ZA201005770B (en) The treatment of damaged skin